EUVIMEDEUVIMED entdecken
Open Access

TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer

Tian Zhong, Jing Zhang, Xingren Liu, Hongmin Li

Cellular Oncology · 2023-10 · 46 (5) · 1493-1507

DOI: 10.1007/s13402-023-00825-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 23.05.2023. Verfasst von Tian Zhong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, C…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Research Foundation from Sichuan Provincial Health and Family Planning Commission of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansCisplatinReactive Oxygen SpeciesUbiquitinationDrug Resistance, NeoplasmCell Line, TumorTripartite Motif ProteinsUbiquitin-Protein LigasesRNA-Binding Proteins

Stichwörter der Autor:innen

Drug resistanceLung cancerOxidative stressRBM38TRIM17

Substanzen

CisplatinReactive Oxygen SpeciesAntineoplastic AgentsTRIM17 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesRBM38 protein, humanRNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
  • Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
  • Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. tomsan2022@126.com.
  • Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China. tomsan2022@126.com.
  • Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China. lihongmin@med.uestc.edu.cn.
  • Cancer Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. lihongmin@med.uestc.edu.cn.

Förderung

  • Research Foundation from Sichuan Provincial Health and Family Planning Commission of China

Zitieren

APA

Zhong, T., Zhang, J., Liu, X., & Li, H. (2023). TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer. Cellular Oncology, 46(5), 1493-1507. https://doi.org/10.1007/s13402-023-00825-6

Vancouver

Zhong T, Zhang J, Liu X, Li H. TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer. Cellular Oncology. 2023;46(5):1493-1507. doi:10.1007/s13402-023-00825-6

BibTeX
@article{Zhong2023,
  author = {Zhong, Tian and Zhang, Jing and Liu, Xingren and Li, Hongmin},
  title = {TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer},
  journal = {Cellular Oncology},
  year = {2023},
  volume = {46},
  number = {5},
  pages = {1493--1507},
  doi = {10.1007/s13402-023-00825-6}
}
Kostenlos starten →